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Abstract Quality of Life (QoL) is the preferred outcome
in non-pharmacological trials, but there is little UK popu-
lation evidence of QoL in epilepsy. In advance of evalu-
ating an epilepsy self-management course we aimed to
describe, among UK participants, what clinical and psy-
cho-social characteristics are associated with QoL. We
recruited 404 adults attending specialist clinics, with at
least two seizures in the prior year and measured their self-
reported seizure frequency, co-morbidity, psychological
distress, social characteristics, including self-mastery and
stigma, and epilepsy-specific QoL (QOLIE-31-P). Mean
age was 42 years, 54% were female, and 75% white.
Median time since diagnosis was 18 years, and 69%
experienced C10 seizures in the prior year. Nearly half
(46%) reported additional medical or psychiatric condi-
tions, 54% reported current anxiety and 28% reported
current depression symptoms at borderline or case level,
with 63% reporting felt stigma. While a maximum QOLIE-
31-P score is 100, participants’ mean score was 66, with a
wide range (25–99). In order of large to small magnitude:
depression, low self-mastery, anxiety, felt stigma, a history
of medical and psychiatric comorbidity, low self-reported
medication adherence, and greater seizure frequency were
associated with low QOLIE-31-P scores. Despite specialist
care, UK people with epilepsy and persistent seizures
experience low QoL. If QoL is the main outcome in epi-
lepsy trials, developing and evaluating ways to reduce
psychological and social disadvantage are likely to be of
primary importance. Educational courses may not change
QoL, but be one component supporting self-management
for people with long-term conditions, like epilepsy.
Keywords Epilepsy  Quality of life  Anxiety 
Depression  Self-mastery  Stigma
Introduction
Drug management enables the majority of people with
epilepsy (PWE) to control their seizures, but in about 40%
seizures persist [1, 2]. Long-term persisting seizures expose
PWE to further risk of psychological and social disad-
vantage, as well as to premature death [3–5]. Barriers to
seizure control include: severe brain pathology, psycho-
logical co-morbidity [6], social disadvantage [7, 8], and
lack of provision of self-management advice and support
[9]. Some of these barriers may be amenable to change
through psychological, social and educational interventions
[10, 11]. None have been tested in the United Kingdom
(UK) by means of a large randomized controlled trial.
In this context, we aimed to recruit a large group of
PWE with persistent seizures from specialist clinics, and
test the effectiveness and cost-effectiveness of a 2-day self-
management education course in an RCT [12]. The UK
National Institute of Clinical Excellence (NICE) and
National Institute of Health Research (NIHR) require evi-
dence of change following complex interventions, with the
primary outcome being quality of life (QoL) [13]. Many
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instruments have been used to measure QoL in randomized
controlled trials with PWE, some more generic and others
adapted specifically for epilepsy, such as the QoL in Epi-
lepsy Scale (QOLIE). A study using a non-epilepsy-
specific QoL measure had been unable to show an
improvement in scores in patients attending self-manage-
ment courses [14]. However, two studies using epilepsy-
specific QoL measures had shown improvements in the
intervention group [15, 16]. In one, some domains of QoL
improved immediately after the intervention, but benefits
did not persist at 6 months [15]. In the other, there had
been co-interventions including monthly appointments
with a pharmacist [16]. It, therefore, remains to be seen
whether an epilepsy-specific QoL measure would improve
following a stand-alone self-management education course
after 1 year.
There is little evidence about QoL among UK PWE
[17, 18]. From international evidence we knew QoL in
epilepsy is multidimensional, and consistently associated
with psychological and epilepsy status [19–21]. Social
characteristics such as stigma, perceived self-mastery, and
the effect of self-management education interventions have
not been measured consistently in international studies
[8, 23, 24]. In this context, and prior to carrying out an
evaluation of the effectiveness of a self-management
course on QoL, we aimed to answer the questions: (1) what
are the clinical, psychological and social characteristics of
UK adults with persistent seizures?; (2) to what extent do
the individual domains of the QoL instrument correlate
with the total measure?; (3) to what extent are clinical,
psychological and social characteristics, which underlie
constructs of QoL, associated with QoL?
Methods
As is recommended we published the trial design and
analysis methods early on [12, 13].
Eligibility criteria
To participate in the trial, patients had to: have a diagnosis
of epilepsy (all epilepsy syndromes) documented by a
specialist, have had at least two self-reported seizures in
the previous 12 months, be currently prescribed anti-
epileptic drugs, be aged C16 years, be able to provide
informed consent, be able to participate in a 2-day epilepsy
self-management course, and be able to complete ques-
tionnaires in English [12]. Exclusion criteria were having
non-epileptic seizures only, having seizures related to an
acute illness or substance overuse, having a serious psy-
chiatric condition or terminal illness, and participating in
other epilepsy-related studies [12].
Recruitment
Participants were recruited from epilepsy clinics at eight
hospitals in South East England. In the context of fre-
quent memory problems reported among PWE [25],
likely lack of harm from this educational intervention,
and to maximise participation, recruitment was by an
opt-out process [26]. Individuals had two opportunities
to opt out by returning a paper slip by pre-paid post: (1)
prior to medical note screening and (2) once deemed
eligible after medical note screening, and prior to contact
by researcher. Thus, patients could opt out of the
recruitment process without having to speak to clinical
staff or a researcher. When being contacted by a
researcher, patients could still verbally decline to enrol
in the study. Participants enrolled into the study were
subsequently asked to give written informed consent at a
face-to-face meeting with a researcher.
The study was approved by the National Research
Ethics Service Committee London—Fulham (REC refer-
ence 12/LO/1962). Trial registration: ISRCTN57937389.
Assessments
Primary and secondary outcomes were used according to
general specifications made by our national funding
agency, with flexibility offered about specific measures
used. The information was obtained by means of a com-
posite questionnaire using validated assessments, which
included the following:
Quality of life
A heath-related epilepsy-specific QoL scale was used, the
QoL in Epilepsy Scale (QOLIE). The QOLIE-31 has dif-
ferent versions. QOLIE-31-P [22] is a modified version of
the QOLIE-31 [27] with added patient-specific weightings.
It contains seven domains reflecting aspects affected by
living with epilepsy: energy, mood, daily activity, cogni-
tion (including memory), medication effects, seizure
worry, and overall QoL. Scores for domains and for total
QOLIE-31-P were calculated according to existing meth-
ods and can range from 0 to 100 [22], with higher scores
indicating better QoL. QoL was included as the primary
outcome because the funding agency specified this.
Demographics
These included age, gender, ethnicity, education, employ-
ment, living arrangements, marital status, and the Index of
Multiple Deprivation (IMD). The IMD measures the level
of deprivation, using participants’ postcode and data from
the UK Office of National Statistics [28] which are
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normalized so a ‘normal’ distribution includes 20% of the
population values in each quintile.
Clinical and psychological characteristics
These included years since diagnosis, number of seizures in
the previous year [3], date of last seizure, and physical/
psychiatric medical history. Current psychological distress
was measured by the 14-item Hospital Anxiety and
Depression Scale (HADS) which classifies cases or bor-
derline cases of anxiety and depression with cut-offs at 0–7
for normal, 8–10 for borderline, C11 for case estimates
[29].
Social and self-management characteristics
Self-management assessments included perceived self-
mastery over epilepsy using an epilepsy-specific scale [30].
Scores range from 6 to 24 with a higher score representing
greater perceived self-mastery. Medication adherence was
recorded using the ten-item Medication Management sub-
scale from the Epilepsy Self-Management Scale [31].
Scores range from 10 to 50, with greater scores indicating
better adherence to medication plans.
To measure the social impact of epilepsy, we assessed
perceived stigma with the Stigma of Epilepsy Scale. It
includes three statements: ‘‘Because of epilepsy, (1) other
people are uncomfortable with me, (2) treat me as inferior,
and (3) prefer to avoid me’’. It is scored on a Likert-type
four-point scale: ‘‘not at all’’, ‘‘yes, maybe’’, ‘‘yes, proba-
bly’’ and ‘‘yes, definitely’’, which is scored from 0 to 9 and
categorized as not stigmatized (score of 0), mild-moderate
(1–6) and highly stigmatized (7–9) [23].
Statistical analysis
The statistical analysis plan for the trial has been described
[13]. To characterize our baseline sample, demographic,
social and clinical data are described using relevant summary
statistics. To describe the QOLIE-31-P instrument, the total
QOLIE-31-P score was used as the dependent variable to test
associations with each of the scale’s individual domains.
Each pairwise combination of the individual domains was
compared to each other using Pearson’s correlation to
determine whether they assess similar components of QoL.
Similarly, we tested whether individual domains were cor-
related with HADS anxiety and depression scores.
To investigate associations between total QOLIE-31-P
score and other baseline measures such as demographics,
simple linear regression analyses were performed. Asso-
ciations between total QOLIE-31-P score and other con-
tinuous measures are represented by Pearson’s correlation
coefficients (r), as above. To assess an association with a
categorical variable, dummy variables were created to
represent the effect of the factor and to select a reference
category, and then F tests were used for the combined
effect of the respective variables. To aid interpretation of
such effects, marginal means (MM) of total QOLIE-31-P
were estimated for each level of the factor variable, and
similarly the MMs were estimated for each quartile of the
continuous variables. Coefficients and MMs from the
simple linear regression are provided with 95% confidence
intervals (CIs), along with p values of significance tests.
For each scale, a category was chosen as a reference for
comparative purposes (‘‘ref’’). For example, when looking
at gender, the category ‘‘male’’ was chosen as a reference
to which the category ‘‘female’’ was compared.
Results
Participant recruitment
Figure 1 illustrates the pathway for those not opting out of
the recruitment process and who had their medical records
screened. From a final group of 1088 eligible patients, 407
participants enrolled in this study, with 404 completing
assessments, representing a 37% recruitment rate.
Description of sample of PWE
Demographics
Demographic characteristics of the sample of people with
poorly controlled epilepsy are described in Table 1. The
average age of participants was 41.7 years (SD 14.1) with
54.2% being female, and three-quarters white (75.3%).
Almost one-third (31.5%) were educated to university degree
level or above. However, almost one half (49.2%) of the total
had no paid work. Most of the PWE lived with at least one
other person (75.5%) and 51% were single. A higher than
national proportion of this group of PWE lived in the most
deprived areas, 60.7% (versus 40%) in IMD quintiles 4 and 5.
Clinical and psychological characteristics
Participants had been diagnosed with epilepsy for a median
of 18 years (range 1–66). This group of PWE reported
frequent seizures, with 69.3% having 10 or more per year.
The median number of days since their last seizure was
34 days (Table 2). Just under half (45.9%) reported co-
morbidity, including 13.2% reporting a prior ‘psychiatric
condition’. HADS scores suggested that a larger propor-
tion, 53.6%, had current borderline or case levels of anx-
iety, and 28% had current borderline or case depression
(Table 2).
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Social and self-management characteristics
A high proportion (63.1%) felt some level of epilepsy-
related stigma (Table 2). The mean score for the perceived
Self-Mastery of Epilepsy Scale was 14.1 (SD 3.3), indi-
cating that on average they felt they had some control over
their condition, with room for improvement. The Medica-
tion Adherence Scale suggested that they felt they followed
their medication plan well, as the average score was 45.4
out of a maximum of 50 (Table 2).
Quality of life
Compared to a maximum possible score of 100, the mean
score on the QOLIE-31-P scale was 66.0 (SD 14.2), with a
wide range from 24.8 to 98.5. When patient-specific
weighting is removed, the QOLIE-31 mean score was 62.0
(SD 15.6), ranging from 24.5–97.6. The seven subscales of
QOLIE-31-P reflecting domains affected by living with
epilepsy are presented in Table 3a. The lowest subscale
score was for energy, followed by cognition (which
includes memory) and seizure worry. Table 3a shows how
each of the QOLIE-31-P subscales contributed a similar
amount to the total score, with strong pairwise correlation
coefficients, ranging from 0.63 to 0.71. This suggests the
QOLIE-31-P is not dominated by a particular subscale. The
correlations between subscales were weaker, suggesting
they are indeed measuring different domains. Table 3b
shows that HADS anxiety is particularly associated with
mood and seizure anxiety domains, whilst HADS depres-
sion is associated with mood, energy and daily activity.
Thus, current psychological distress is associated with
participants’ perception that QoL is reduced.
Associations of demographic, clinical and psycho-
social factors with QOLIE-31-P
Demographics
Total QOLIE-31-P scores were found to be moderately
associated with several demographic factors (Table 4).
Females had lower scores than males (females MM: 64.2;
males MM: 68.2). Less education (no formal qualifications
MM: 61.8; higher education MM: 68.3) and not being
employed (not employed MM: 62.0; employed MM: 69.5)
were associated with lower QOLIE-31-P scores.
Clinical and psychological characteristics
Amore recent diagnosis of epilepsy (p = 0.037) and a higher
seizure frequency, specifically with 10 or more seizures in the
past year (C10 seizures MM: 64.0; 1–3 seizures MM: 73.6),
were associated with a moderately lower total QOLIE-31-P
score. Reporting prior co-morbidity, especially psychiatric,
was associated with lower QoL (both medical and psychiatric
MM: 56.8; no co-morbidity MM: 68.5). Current borderline or
case scores for anxiety or depression determined by HADS
were associated with the greatest reductions in QOLIE-31-P
scores (no anxiety MM: 74.4; anxiety case MM: 56; no
depression MM: 70.8; depression case MM: 47.2). Pairwise
correlations of current depression and anxiety HADS scores
Fig. 1 Participant recruitment process. In the first stage of opt-outs,
an invitation letter was sent by consultants to patients who had
attended their clinic in the past year (not illustrated here), with a
3-week window to opt out from future contact. Medical notes of
patients not opting out were screened for eligibility criteria. Ineligi-
bility at this stage was primarily not having at least two seizures in the
previous year. In combination, the opt-out stages involved two
invitation letters and two opportunities to opt out resulting in 1986
participants remaining in the pathway. Three attempts were made to
contact patients and research workers contacted 1458 patients.
Eligibility was assessed once again. Ineligibility at this stage was
primarily not having two seizures within the past year or living
outside the study’s catchment area. 681 patients verbally declined to
participate and finally 404 participants consented and assessed for
baseline data. These participants were randomized into treatment
groups for the study. Grey boxes indicate the number of individuals
who opted out/declined or were not eligible for the study
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with total QOLIE-31-P showed that they were closely asso-
ciated (q = -0.66, andq = -0.63, respectively) (Fig. 2a, b).
Social and self-management characteristics
Table 4 shows that lower scores on the Self-Mastery Scale
were associated with much lower total QOLIE-31-P scores
(self-mastery—highest quartile MM: 70; lowest MM:
49.2). Felt stigma (no stigma MM: 71.6; highly stigmatized
MM: 58.9) and less medication adherence were also
associated with lower total QOLIE-31-P scores. Pairwise
correlations of self-mastery and stigma scores with total
QOLIE-31-P show their association (q = 0.49, p\ 0.001
(Fig. 2c) and q = -0.31, p\ 0.001).
Discussion
Summary of findings
Due to the restrictions on data that can be legally collected
from non-participants, we are unable to evaluate
characteristics of those not consenting to the study. Com-
pared to the population of London, our study group was
older than the average of 34.0 years, with more white
ethnicities, and a greater proportion living in areas of high
deprivation [32]. Our group had a higher proportion of
people that were single (43.8% vs national statistics:
33.9%) and living with others (75.5% vs national statistics:
60.6%) [33]. Our group of PWE was relatively highly
educated with 51.3% having post-secondary qualifications
which is close to national figures of 62.6%. Yet despite
this, 49.2% were unemployed. Figures for London, UK
show 28.5% of people not in work (unemployed and eco-
nomically inactive between 16 and 64) [34]. Thus, in
comparison to general population statistics, the members
of our group of PWE with continuing seizures experiences
more unemployment, live more with others in areas with
high deprivation and are more likely to be single.
Among these UK adults with persistent seizures
recruited from specialist clinics, their experience of having
epilepsy was long, with a median of 18 years since diag-
nosis, and their epilepsy was difficult to control, with the
majority (69%) experiencing 10 or more seizures in the
Table 1 Participant demographics
Factor Level n = 404
Age mean (SD) [range] 41.7 (14.1) [16, 85]
Gender n (%) Female 219 (54.2)
Male 185 (45.8)
Ethnicity n (%) White 304 (75.3)
Mixed/multiple ethnic groups 40 (9.9)
Asian/Asian British 18 (4.5)
Black/African/Caribbean/Black British 33 (8.2)
Other 9 (2.2)
Educationa n (%) No formal qualifications 61 (15.1)
Secondary 131 (32.4)
Further education 85 (21.0)
Higher education 127 (31.5)
Employment (B64 years) n (%) (n = 382) Specifically employed or student 194 (50.8)
Not employed 188 (49.2)
Living arrangements n (%) Living with others 305 (75.5)
Living alone 95 (23.5)
Marital status n (%) (n = 402) Single 205 (51.0)
Steady relationship but not cohabiting 44 (11.0)
Married/living with partner 153 (38.1)
IMD quintiles n (%) 1 (least deprived) 39 (9.7)
2 56 (13.9)
3 64 (15.8)
4 136 (33.7)
5 (most deprived) 109 (27.0)
a Further education: any qualification obtained post-secondary level, excluding university level. Higher education: Bachelor’s degree and higher
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previous year. Nearly half (45.8%) reported an additional
history of a medical or psychiatric condition. Anxiety
symptoms were twice as common as symptoms of
depression (54 vs 28%). An even greater proportion of
participants (63.1%) reported feeling to some extent
stigmatized.
QoL measured by QOLIE-31-P had a mean score of 66
and varied widely over a range of 74 points. Factors that
were associated with diminished total QOLIE-31-P were:
depression, low self-mastery, anxiety, greater felt stigma, a
history of medical and psychiatric comorbidity, low med-
ication adherence, and greater seizure frequency, in
decreasing order of effect.
Generalizability of sample
A key strength of this study is that it recruited from a
large group of PWE attending publicly funded epilepsy
clinics, and results are likely to be generalizable to
people in countries where medical care is also publically
funded [26]. In such contexts, income is not a main
factor in receiving access to health care. Studies from
the USA find low QoL in epilepsy is associated with
lower income [32]. We did not find that levels of
deprivation were associated with QoL. Recruiting vol-
unteers via advertisements or through user groups also
requires an active response from patients, and may result
in a patient group taking a more active role in managing
their condition which may not be representative of the
whole population [26]. An opt-out process can help with
recruiting patients with memory problems, which can be
a challenge to recruitment in epilepsy [35]. We had a
relatively high recruitment rate at 37%, which is higher
than a previous trial recruiting PWE [7]. Our current
trial population does not represent the 60% of PWE
without two or more seizures in the prior year, nor does
it necessarily represent PWE with and without persistent
seizures who are managed by doctors without referral to
an epilepsy specialist. A small UK cohort study has
found PWE recruited in primary care, at least 60% of
whom would have epilepsy without persistent seizures,
had a higher mean QOLIE-31 of 70 [18].
Table 2 Clinical,
psychological, social and self-
management assessments of
PWE
Scale Result
Years since epilepsy diagnosis, mean (SD); median,[range] (n = 403) 21.2 (15.5); 18 [1, 66]
Seizure frequency n (%), (n = 404)
1–3 49 (12.1)
4–5 51 (12.6)
7–9 24 (5.9)
10? 280 (69.3)
Days since last seizure (n = 383), median (IQR) [range] 34 (18, 63) [1, 351]
Co-morbidities n (%)
No 219 (54.2)
Yes, another medical condition 132 (32.7)
Yes, psychiatric condition 20 (5.0)
Yes, both medical and psychiatric conditions 33 (8.2)
HADS anxiety n (%), (n = 403)
Normal (0–7) 187 (46.4)
Borderline (8–10) 79 (19.6)
Case (C11) 137 (34.0)
HADS depression n (%), (n = 403)
Normal (0–7) 290 (72.0)
Borderline (8–10) 71 (17.6)
Case (C11) 42 (10.4)
Stigma of epilepsy n (%), (n = 401)
Not stigmatized (0) 148 (36.9)
Mild-moderate (1–6) 203 (50.6)
Highly stigmatized (7–9) 50 (12.5)
Self-Mastery of Epilepsy Scale, mean (SD) [range], (n = 399) 14.1 (3.3) [6, 24]
Medication Adherence Scale, mean (SD) [range], (n = 399) 45.4 (4.8) [16.7, 50]
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Implications for clinical practice and research
Evidence from our UK group is consistent with evidence
internationally that PWE and particularly those with per-
sistent, frequent seizures have important psycho-social
disadvantage and impaired QoL [8, 17, 19–21, 23, 24, 36].
Although our group had experienced epilepsy for a median
of 18 years, these disadvantages have seemingly not been
identified or, if identified, not redressed in usual medical
care. Nevertheless, their QOLIE-31 scores were compara-
ble to studies reported from other countries for people with
and without persistent seizures. The UK group’s mean
QOLIE-31 was 62 (SD 15.6) compared to a global mean
score of 59.8 (SD 8.0) [17]. The wide range in UK mean
QOLIE-31 scores (24.5–97.6) overlap the means reported
in the lowest and highest scoring countries, the Russian
Federation mean 42.1 (SD 4.1), and Canada mean 82 (SD
32.8), respectively [17].
Luoni et al. suggest that when epilepsy is accompanied
by persistent seizures there is ‘a diagnostic gap’ when it
comes to depression [36]. Screening for depression has
been recommended [19, 20] but is still not routine. In
epilepsy with persistent seizures, anxiety symptoms are
even more common, and this is another diagnostic gap
[37]. Many specialists work in isolation, with insufficient
multi-disciplinary team support to address mental health
issues, even if they are identified. If mental health issues
are not redressed, there is likely over time to be a vicious
cycle of negative consequences [3–5]. This requires
exploration with longitudinal research, and development
and testing of interventions to redress the gap. Research has
begun on interventions aimed to reduce psychological
distress, and because of their association, such interven-
tions are more likely to affect QoL [38]. This research has
not necessarily focused on people with poorly controlled
epilepsy, who are likely to be most affected by psycho-
logical distress, and require intervention [10, 11].
Compared to other stigmatized conditions, there has
thus far been less focus on testing interventions to reduce
social impairment, such as stigma, lack of social support
and lack of self-mastery in epilepsy care [8, 31]. Stigma,
lack of social support and low self-mastery are potentially
amenable to change. Moreover, it has been proposed that
improving self-esteem and self-mastery is prerequisite if
education is to lead to behaviour change [10, 31, 39]. In
other stigmatized conditions, like HIV and mental ill-
health, group interventions have been developed and tested
specifically to provide social support, and to prevent
Table 3 Pearson’s correlation coefficients (r) between (a) all pairwise combinations of total and domain sub-scores of QOLIE-31-P and (b) total
and domain sub-scores of QOLIE-31-P with HADS
(a)
QOLIE-31-P Score mean (SD) [range] Total Energy Mood Daily activity Cognition Medication effects Seizure worry
Total 66.0 (14.2) [24.8, 98.5]
Energy 53.4 (18.1) [16.7, 100] 0.68
Mood 67.2 (17.6) [16.7, 100] 0.67 0.53
Daily activity 65.2 (23.5) [19.3, 100] 0.71 0.42 0.39
Cognition 59.2 (23.6) [18.6, 100] 0.68 0.44 0.44 0.43
Medication effects 67.7 (23.8) [21.7, 100] 0.68 0.33 0.27 0.47 0.38
Seizure worry 61.8 (21.7) [24.0, 100] 0.63 0.34 0.40 0.44 0.40 0.43
Overall QoL 62.6 (18.2) [10.0, 100] 0.67 0.55 0.65 0.43 0.44 0.25 0.38
(b)
Scale Correlation coefficient (HADS-A) Correlation coefficient (HADS-D)
QOLIE-31-P scale (n = 400) -0.63 -0.66
QOLIE-31-P subscales
Energy (n = 402) -0.46 -0.57
Mood (n = 402) -0.67 -0.60
Daily activity (n = 400) -0.40 -0.51
Cognition (n = 402) -0.42 -0.46
Medication effects (n = 399) -0.35 -0.37
Seizure worry (n = 401) -0.51 -0.35
Overall quality of life (n = 400) -0.45 -0.56
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isolation, loss of confidence, and self-stigma early on after
diagnosis [40, 41]. People with epilepsy in the UK and
elsewhere would benefit from this approach.
A question remains as to whether stand-alone educa-
tional interventions are likely to improve QoL. Memory
problems are more prevalent among PWE with persistent
seizures [25, 35]. Questions about memory are included in
the cognitive subscale of the QOLIE-31 [22, 27], and so
they may affect the total score. Memory issues are likely to
make learning about self-management more challenging
for PWE, with persistent seizures. Some studies report an
improvement in epilepsy knowledge following self-man-
agement courses with follow-up at 6 months, at most
[14, 42]. Long-term assessments have not been done, thus
it is not known what impact memory would have on
knowledge. A measure of acquired knowledge was not
included in our study due to the volume of outcomes
mandated by program funders. One hypothesis was that
other measures, such as self-mastery, medication adher-
ence and seizure frequency, could improve with increased
knowledge. In the UK and other European countries, epi-
lepsy nurses are taking an increasing role reinforcing
advice about self-management [43–45] which could reduce
the impact of memory issues. Self-management education,
which is reinforced over time by a co-intervention of
advice from a nurse or other professional, seems more
likely to promote QoL [16, 43, 46].
Conclusion
In common with PWE internationally, UK PWE reports
impaired QoL compared to the general population and to
PWE managed in primary care [17, 18]. The impairment in
QoL in this large group of PWE with persistent seizures
was significantly associated with symptoms of depression,
lack of sense of self-mastery, anxiety, felt stigma and high
seizure frequency, in diminishing order. Given this, stand-
alone educational interventions may not be sufficient to
change QoL. The close association of QoL and psycho-
logical distress supports a hypothesis that developing and
bFig. 2 Relationships between quality of life, psychological and self-
management assessments in people with epilepsy. Quality of life in
epilepsy was measured by QOLIE-31-P. a Anxiety, measured by
HADS, was significantly associated with total QOLIE-31-P scores
(r = -0.63, p\ 0.001, n = 400). b Depression, measured by HADS,
was significantly associated with total QOLIE-31-P scores
(r = -0.66, p\ 0.001, n = 400). c Self-mastery over epilepsy was
significantly associated with total QOLIE-31-P scores (r = 0.49,
p\ 0.001, n = 399). Red line represents the fitted simple regression
model
J Neurol (2017) 264:1174–1184 1181
123
Table 4 Participant characteristics and associations with QOLIE-31-P
Baseline characteristics (categorical) Marginal mean (95%
CI)
Coefficient (95%
CI)
p value
Scale Level
Gender (n = 400) Male (ref) 68.2 (66.2, 70.3) – 0.0043
Female 64.2 (62.3, 66.1) -4.1 (-6.8, -1.3)
Highest level of education achieved
(n = 400)
Higher education (ref) 68.3 (65.9, 70.8) – 0.0096
Further education 67.8 (64.8, 70.8) -0.5 (-4.4, 3.4)
Secondary 64.6 (62.2, 67.1) -3.7 (-7.1, -0.2)
No formal qualifications 61.8 (58.2, 65.3) -6.6 (-10.9,
-2.2)
Employment status (B64 years) (n = 379) Employed or student (ref) 69.5 (67.5, 71.4) – \0.001
Not employed 62.0 (60.0, 64.0) -7.5 (-10.3,
-4.7)
Years since epilepsy diagnosis (n = 403) 32 years 67.1 (65.4, 68.8) 0.1 (0.01, 0.2) 0.037
18 years 65.7 (64.3, 67.2)
8 years 64.8 (62.9, 66.6)
1 year 64.1 (61.8, 66.4)
Seizure frequency in previous 12 months
(n = 400)
1–3 times (ref) 73.6 (69.7, 77.5) – \0.001
4–6 times 68.8 (64.9, 72.6) -4.8 (-10.3, 0.7)
7–9 times 69.3 (63.7, 74.8) -4.3 (-11.1, 2.5)
10? times 64.0 (62.3, 65.6) -9.6 (-13.9,
-5.4)
Co-morbidity (n = 400) No (ref) 68.5 (66.6, 70.3) – \0.001
Yes, another medical condition 65.0 (62.7, 67.4) -3.4 (-6.4, -0.4)
Yes, psychiatric condition 61.5 (55.4, 67.6) -7.0 (-13.4,
-6.4)
Yes, both medical and psychiatric
conditions
56.8 (52.1, 61.6) -11.6 (-16.7,
-6.6)
HADS anxiety (n = 399) Normal (ref) 74.4 (72.7, 76.1) – \0.001
Borderline 63.7 (61.1, 66.3) -10.7 (-13.8,
-7.6)
Case 56.0 (54.1, 58.0) -18.4 (-21.0,
-15.8)
HADS depression (n = 399) Normal (ref) 70.8 (69.4, 72.1) – \0.001
Borderline 58.1 (55.4, 60.8) -12.7 (-15.7,
-9.6)
Case 47.2 (43.6, 50.7) -23.6 (-27.4,
-19.8)
Stigma of epilepsy (n = 397) Not stigmatized (ref) 71.6 (69.4, 73.8) – \0.001
Mild-moderate 63.9 (62.1, 65.8) -7.7 (-10.6,
-4.8)
Highly stigmatized 58.9 (55.1, 62.6) -12.8 (-17.1,
-8.4)
Self-Mastery of Epilepsy Scale (n = 396) 16 self-mastery score 70.0 (68.6, 71.4) 2.1 (1.7, 2.5) \0.001
14 self-mastery score 65.9 (64.7, 67.1)
12 self-mastery score 61.7 (60.3, 63.1)
6 self-mastery score 49.2 (46.0, 52.4)
Medication Adherence Scale (n = 399) 48 med adherence score 66.8 (65.2, 68.3) 0.3 (0.05, 0.6) 0.023
46 med adherence score 66.1 (64.7, 67.5)
43 med adherence score 65.1 (63.5, 66.6)
16 med adherence score 55.9 (47.3, 64.6)
(ref) refers to the category used as a reference for comparison
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testing stepped-up psychological interventions are more
likely to improve QoL. In addition, social interventions,
which aim to provide peer support and reduce stigma, may
also improve QoL, especially early on after diagnosis
[40, 41]. If psycho-social interventions result in more self-
confidence, information derived from courses, provided as
co-interventions or subsequently, may be more likely to
promote QoL and self-management practice.
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